Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis

Award Number: R43EY025123
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/03/2015
PERIOD OF PERFORMANCE END DATE: 01/31/2017

Group Awards By:

View Award Description

Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis - DESCRIPTION (provided by applicant): The age-related macular degeneration (AMD) characterized by the formation of subretinal choroidal neovascularization is the main cause of blindness in the elderly. Vascular endothelial growth factor (VEGF) regulates angiogenesis and enhances vascular permeability that results in visual acuity deterioration. Blockade of VEGF action is currently the most effective strategy in preventing choroidal angiogenesis and reducing vascular permeability. The intravitreal injection of anti-VEGF drugs has been widely employed to reduce the disease progression and improve the visual outcomes of the affected patients. Unfortunately, intravitreal injection requires the administration in hospital, poses a risk of sevee infection, retinal detachment, cataract, endophthalmitis, intraocular inflammation, increase of intraocular pressure and vitreous hemorrhage as well as has low patient compliance. Abzyme Therapeutics LLC proposes to develop a new therapeutic for self-administrable noninvasive topical delivery to inhibit abnormal angiogenesis in the retina and choroid. The anti-neovascularization therapeutic for AMD treatment will be designed to overcome the retinal and choroidal barriers such that the therapeutic can be delivered in the form of eye drop. Active anti-angiogenesis therapeutics will reach the VEGF target in the vitreous humor via transferrin receptor (TfR) mediated transcytosis and transcorneal transport. In Phase I, human single domain high affinity anti-VEGF neutralizing nanobodies and bispecific VEGF/TfR nanobodies with low affinity to TfR and high affinity to VEGF will be produced. The accumulation of nanobodies in the vitreous humor and retina will be determined in a mouse model that receives topical eye drops. In Phase II, the anti-neovascularization activity of transferrin receptor- mediated anti-VEGF therapeutics will be characterized and validated in animal AMD models pursuing the IND application.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2015	ABZYME THERAPEUTICS, LLC	321 JONES BLVD, STE 300	POTTSTOWN	PA	19464	MONTGOMERY	USA	Vision Research	000	1	4/5/2017	NEW	$0
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $224,935 )
2015	2015	ABZYME THERAPEUTICS LLC	271 GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Vision Research	000	1	2/3/2015	NEW	$224,935
														Subtotal = $224,935

Grand Total All Awards = $224,935

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis

Award Number: R43EY025123

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/03/2015

PERIOD OF PERFORMANCE END DATE: 01/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer